Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:56 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

ClinicalTrials.gov · NCT04649580 · Registry updated: 2024-12-17

Condition / research focus: Neuroendocrine Tumours (NET)
Sponsor: Ipsen
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2021-04-27. Completion: 2022-06-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 5 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Site recruitment: Not reported
Cardiff and Vale University LHB
Cardiff, United Kingdom
Site recruitment: Not reported
University Hospitals Coventry and Warwickshire NHS Trust
Coventry, United Kingdom
Site recruitment: Not reported
Liverpool University Hospitals NHS Foundation Trust
Liverpool, United Kingdom
Site recruitment: Not reported
Royal Free London NHS Foundation Trust
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

ClinicalTrials.gov · NCT04852679 · Registry updated: 2024-10-01

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumor
Sponsor: Ipsen
Countries with listed sites: China
Registry dates and results: Start: 2021-05-24. Completion: 2023-01-13 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel (drug)

Where the study takes place — 14 listed sites

Cancer Hospital Chinese Academy of Sciences
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University Third Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Site recruitment: Not reported
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Qilu Hospital Of Shandong University
Jinan, Shandong, China
Site recruitment: Not reported
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Fudan University Shanghai Cancer Centre
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital Of Xi'an Jiaotong University
Xi’an, Shanxi, China
Site recruitment: Not reported
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
The second affiliated hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site recruitment: Not reported
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

ClinicalTrials.gov · NCT06607666 · Registry updated: 2024-09-23

Condition / research focus: Acromegaly
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Countries with listed sites: Italy
Registry dates and results: Start: 2023-01-26. Completion: 2024-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel (drug) — also listed as: Somatostatin Receptor ligand

Where the study takes place — 1 listed sites

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC ENDOCRINOLOGIA
Roma, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

ClinicalTrials.gov · NCT05701241 · Registry updated: 2024-06-14

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumor
Sponsor: University Hospital, Antwerp
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2023-06-28. Completion: 2034-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Somatostatin analog (drug) — also listed as: lanreotide, octreotide, sandostatin, somatuline

Where the study takes place — 19 listed sites

AZ Klina
Brasschaat, Antwerp, Belgium
Site recruitment: Recruiting
AZ Rivierenland
Rumst, Antwerp, Belgium
Site recruitment: Active, not recruiting
Ghent University Hospital
Ghent, East Flanders, Belgium
Site recruitment: Active, not recruiting
VITAZ
Sint-Niklaas, East-Flanders, Belgium
Site recruitment: Recruiting
University Hospital Leuven
Leuven, Flemish Brabant, Belgium
Site recruitment: Recruiting
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium
Site recruitment: Active, not recruiting
AZ Monica
Antwerp, Belgium
Site recruitment: Not yet recruiting
GZA
Antwerp, Belgium
Site recruitment: Active, not recruiting
Ziekenhuis Netwerk Antwerpen
Antwerp, Belgium
Site recruitment: Withdrawn
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Site recruitment: Recruiting
H.U.B.
Brussels, Belgium
Site recruitment: Active, not recruiting
Antwerp University Hospital
Edegem, Belgium
Site recruitment: Recruiting
Centre Hospitalier Universitaire Sart Tilman
Liège, Belgium
Site recruitment: Active, not recruiting
Rijnstate
Arnhem, Gelderland, Netherlands
Site recruitment: Recruiting
Maastricht UMC+
Maastricht, Limburg, Netherlands
Site recruitment: Recruiting
Maxima Medisch Centrum
Eindhoven, North Brabant, Netherlands
Site recruitment: Active, not recruiting
Amsterdam UMC
Amsterdam, North Holland, Netherlands
Site recruitment: Active, not recruiting
UMC Groningen
Groningen, Netherlands
Site recruitment: Recruiting
Erasmus MC
Rotterdam, Netherlands
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

ClinicalTrials.gov · NCT01070758 · Registry updated: 2024-04-18

Condition / research focus: Congenital Hyperinsulinism
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2010-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel (drug) — also listed as: Somatuline autogel

Where the study takes place — 1 listed sites

Pediatric Endocrinology Unit, Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET

ClinicalTrials.gov · NCT05922579 · Registry updated: 2024-02-29

Condition / research focus: Neuroendocrine Tumors
Sponsor: Ipsen
Countries with listed sites: Australia
Registry dates and results: Start: 2023-06-15. Completion: 2023-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

CAPPRE
Sydney, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

ClinicalTrials.gov · NCT02859064 · Registry updated: 2023-12-05

Condition / research focus: Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors
Sponsor: SCRI Development Innovations, LLC
Countries with listed sites: United States
Registry dates and results: Start: 2017-07-28. Completion: 2022-06-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline® Depot Injection
Y-90 microspheres (device) — also listed as: SIR-Spheres

Where the study takes place — 3 listed sites

Rocky Mountain Cancer Center
Denver, Colorado, United States
Site recruitment: Not reported
Research Medical Center/HCA Midwest
Kansas City, Missouri, United States
Site recruitment: Not reported
Tennessee Oncology PLLC
Nashville, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

ClinicalTrials.gov · NCT03043664 · Registry updated: 2023-06-29

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumors
Sponsor: Duke University
Countries with listed sites: United States
Registry dates and results: Start: 2017-07-01. Completion: 2022-06-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline Depot
Pembrolizumab (drug) — also listed as: Keytruda

Where the study takes place — 2 listed sites

Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Lexington Medical Center
Columbia, South Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

ClinicalTrials.gov · NCT03967249 · Registry updated: 2023-03-22

Condition / research focus: Acromegaly
Sponsor: Ionis Pharmaceuticals, Inc.
Countries with listed sites: Hungary · Lithuania · Poland · Russia · Serbia · United States
Registry dates and results: Start: 2019-07-25. Completion: 2022-07-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IONIS GHR-LRx (drug)
Somatostatin Receptor Ligand (SRL) (drug) — also listed as: lanreotide, octreotide

Where the study takes place — 22 listed sites

University of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
Northwestern University
Evanston, Illinois, United States
Site recruitment: Not reported
Palm Research Center, Inc.
Las Vegas, Nevada, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Not reported
Oregon Health & Science University
Portland, Oregon, United States
Site recruitment: Not reported
Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly
Budapest, Hungary
Site recruitment: Not reported
Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos - Endocrinology clinic
Kaunas, Lithuania
Site recruitment: Not reported
Vaidoto Urbanaviciaus Individuali imone - Endokrinologijos klinika
Vilnius, Lithuania
Site recruitment: Not reported
Centrum Nowoczesnych Terapii "Dobry Lekarz" Sp. z o. o.
Krakow, Poland
Site recruitment: Not reported
Twoja Przychodnia - Centrum Medyczne Nowa Sol
Nowa Sól, Poland
Site recruitment: Not reported
Mazowiecki Szpital Brodnowski
Warsaw, Poland
Site recruitment: Not reported
Multi-field Medical Clinic Anturium LLC
Barnaul, Russia
Site recruitment: Not reported
Interregional Clinical Diagnostic Center
Kazan', Russia
Site recruitment: Not reported
Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev
Kemerovo, Russia
Site recruitment: Not reported
Federal State Budget Institution "National Medical Research Center of Endocrinology" of the Ministry of Healthcare of the Russian Federation
Moscow, Russia
Site recruitment: Not reported
I.M. Sechenov Moscow First State Medical University
Moscow, Russia
Site recruitment: Not reported
Novosibirsk State Regional Clinical Hospital
Novosibirsk, Russia
Site recruitment: Not reported
Orenburg Regional Clinical Hospital
Orenburg, Russia
Site recruitment: Not reported
Almazov National Medical Research Centre
Saint Petersburg, Russia
Site recruitment: Not reported
State Budget Healthcare Institution of the Tver Region (Regional Clinical Hospital)
Tver', Russia
Site recruitment: Not reported
Clinical Center of Serbia
Belgrade, Serbia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

ClinicalTrials.gov · NCT01923649 · Registry updated: 2023-01-27

Condition / research focus: Dumping Syndrome
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium
Registry dates and results: Start: 2008-04. Completion: 2013-12-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide 90 mg slow release formulation (drug) — also listed as: Somatulin autogel
Placebo (drug)

Where the study takes place — 3 listed sites

AZ St. Lucas
Brugges, Belgium
Site recruitment: Not reported
ZOL Genk
Genk, Belgium
Site recruitment: Not reported
University Hospitals Leuven
Leuven, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3TerminatedINTERVENTIONAL

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

ClinicalTrials.gov · NCT02288377 · Registry updated: 2023-01-18

Condition / research focus: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Sponsor: Federation Francophone de Cancerologie Digestive
Countries with listed sites: Belgium · France · Germany · United Kingdom
Registry dates and results: Start: 2015-01. Completion: 2020-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (drug)
Placebo (drug)

Where the study takes place — 24 listed sites

Clinique Universitaire saint-Luc
Brussels, Belgium
Site recruitment: Not reported
CHU d'Angers - Hôtel Dieu
Angers, France
Site recruitment: Not reported
CHU - Hôpital Avicenne
Bobigny, France
Site recruitment: Not reported
CHU Côte de Nacre
Caen, France
Site recruitment: Not reported
CHU Estaing
Clermont-Ferrand, France
Site recruitment: Not reported
Hôpital Beaujon
Clichy, France
Site recruitment: Not reported
CHU Le Bocage Service d'HGE
Dijon, France
Site recruitment: Not reported
CH Les Oudairies
La Roche-sur-Yon, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
CHU La Timone
Marseille, France
Site recruitment: Not reported
Hôpital de la Source
Orléans, France
Site recruitment: Not reported
CHU Cochin
Paris, France
Site recruitment: Not reported
Hôpital Haut Lévêque Bat Magellan, Service d'hépato-gastroentérologie
Pessac, France
Site recruitment: Not reported
Hôpital de la Milétrie
Poitiers, France
Site recruitment: Not reported
Hôpital Robert Debré
Reims, France
Site recruitment: Not reported
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
Site recruitment: Not reported
CHU Charles Nicolle
Rouen, France
Site recruitment: Not reported
CHU de Saint Etienne
Saint-Priest-en-Jarez, France
Site recruitment: Not reported
Hôpital Rangueil
Toulouse, France
Site recruitment: Not reported
Institut Gustave Roussy
Villejuif, France
Site recruitment: Not reported
Charite Campus Virchow Kilikum
Berlin, Germany
Site recruitment: Not reported
University Hospital Marburg
Marburg, Germany
Site recruitment: Not reported
Royal Free Hospital Neuroendocrine Tumour Unit
London, United Kingdom
Site recruitment: Not reported
Manchester Academic Health Sciences Centre (MAHSC)
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Acromegaly Combination Treatment Study

ClinicalTrials.gov · NCT01538966 · Registry updated: 2023-01-04

Condition / research focus: Acromegaly
Sponsor: Cedars-Sinai Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2012-03-29. Completion: 2022-05-20 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pegvisomant (drug) — also listed as: Somavert
Octreotide LAR (drug) — also listed as: Sandostatin
Lanreotide (drug) — also listed as: Somatuline

Where the study takes place — 1 listed sites

Cedars-Sinai Medical Center
Los Angeles, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

ClinicalTrials.gov · NCT00774930 · Registry updated: 2022-10-14

Condition / research focus: Carcinoid Syndrome
Sponsor: Ipsen
Countries with listed sites: Brazil · Czechia · India · Latvia · Poland · Russia · Serbia · South Africa · Turkey (Türkiye) · Ukraine · United States
Registry dates and results: Start: 2009-05. Completion: 2015-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline, Somatuline Depot, Somatuline Autogel, Lanreotide Autogel
Placebo (drug)

Where the study takes place — 54 listed sites

VA Greater Los Angeles Health Care System
Los Angeles, California, United States
Site recruitment: Not reported
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
Site recruitment: Not reported
Stanford Cancer Center
Stanford, California, United States
Site recruitment: Not reported
Cedars Sinai Outpatient Cancer Center
West Hollywood, California, United States
Site recruitment: Not reported
Kentuckiana Cancer Institute
Louisville, Kentucky, United States
Site recruitment: Not reported
Louisiana State University Health Science Center
Kenner, Louisiana, United States
Site recruitment: Not reported
University of Michigan
Ann Arbor, Michigan, United States
Site recruitment: Not reported
University of Mississippi Medical Center
Jackson, Mississippi, United States
Site recruitment: Not reported
University of New Mexico Cancer Care Center
Albuquerque, New Mexico, United States
Site recruitment: Not reported
Providence Portland Medical Center
Portland, Oregon, United States
Site recruitment: Not reported
Oregon Health Science University
Portland, Oregon, United States
Site recruitment: Not reported
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Site recruitment: Not reported
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
UPMC Liver Cancer Center
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported
Eastern Virginia Medical School
Norfolk, Virginia, United States
Site recruitment: Not reported
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
Biocancer - Centro de Pesquisa e Tratamento do Câncer
Belo Horizonte, Brazil
Site recruitment: Not reported
Hospital LifeCenter
Belo Horizonte, Brazil
Site recruitment: Not reported
Oxion Medicina Oncológica
Belo Horizonte, Brazil
Site recruitment: Not reported
Hospital Universitário de Brasilia
Brasília, Brazil
Site recruitment: Not reported
Hospital Erasto Gaertner
Curitiba, Brazil
Site recruitment: Not reported
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Brazil
Site recruitment: Not reported
Hospital de Base de São José do Rio Preto
São José do Rio Preto, Brazil
Site recruitment: Not reported
VFN Onkologicka klinika
Prague, Czechia
Site recruitment: Not reported
Sir Gangaram Hospital
Delhi, India
Site recruitment: Not reported
Indo-American Cancer Institute & Research Centre
Hyderabad, India
Site recruitment: Not reported
Omega Hospitals
Hyderabad, India
Site recruitment: Not reported
Santokaba Durlabhji Memorial Hospital and Research Institute
Jaipur, India
Site recruitment: Not reported
Bhagwan Mahaveer cancer hospital and research centre
Jaipur, India
Site recruitment: Not reported
Shatabdi Super Speciality hospital
Mumbai, India
Site recruitment: Not reported
Tata Memorial Hospital
Mumbai, India
Site recruitment: Not reported
Paul Stradins Clinical University Hospital
Riga, Latvia
Site recruitment: Not reported
Klinika Endokrynologii, Diabetologii i Leczenia Izotopami
Wroclaw, Poland
Site recruitment: Not reported
Non-Federal Institution of Healthcare "Central Clinical Hospital # 1 of the LLC "Russian Railways (RZD)"
Moscow, Russia
Site recruitment: Not reported
Russian Academy of Medical Sciences "Russian Oncological Research Centre named after N.N. Blokhin RAMS"
Moscow, Russia
Site recruitment: Not reported
Federal Institution of Healthcare "Leningradsky Regional Oncological Dispensary"
Saint Petersburg, Russia
Site recruitment: Not reported
Clinic of Endocrinology, diabetes and metabolic diseases, Clinical Center of Serbia
Belgrade, Serbia
Site recruitment: Not reported
Oncology Institute of Vojvodina, Sremska Kamenica
Kamenitz, Serbia
Site recruitment: Not reported
Rondebosch Oncology Unit
Cape Town, South Africa
Site recruitment: Not reported
Groote Schuur Hospital
Cape Town, South Africa
Site recruitment: Not reported
Westridge Medical Centre
Durban, South Africa
Site recruitment: Not reported
GVI Oncology Clinical Trial Unit
Port Elizabeth, South Africa
Site recruitment: Not reported
Erciyes University Medical Faculty
Kayseri, Turkey (Türkiye)
Site recruitment: Not reported
Cherkassy Regional Oncology Dispensary
Cherkassy, Ukraine
Site recruitment: Not reported
Chernivtsi Regional Oncology Center
Chernivtsi, Ukraine
Site recruitment: Not reported
Oncology and Medical Radiology Chair of Dnepropetrovsk State Medical Academy
Dnipro, Ukraine
Site recruitment: Not reported
Regional Anticancer Center, Department of oncoproctology
Donetsk, Ukraine
Site recruitment: Not reported
Municipal Clinical Hospital #2, Proctology department
Kharkiv, Ukraine
Site recruitment: Not reported
Kyiv City Oncological Hospital, Thoracic department
Kyiv, Ukraine
Site recruitment: Not reported
Medical Centre "Mriya"
Kyiv, Ukraine
Site recruitment: Not reported
National Cancer Institute
Kyiv, Ukraine
Site recruitment: Not reported
Odessa Regional Clinical Hospital
Odesa, Ukraine
Site recruitment: Not reported
Uzhgorods'ka Tsentral'na Mis'ka Klinichna Likarnya, Mis'kyy Onkologichnyy Tsentr
Uzhhorod, Ukraine
Site recruitment: Not reported
Vinnytsya Regional Clinical Oncological Center, Vinnytsya State Medical University
Vinnytsia, Ukraine
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

ClinicalTrials.gov · NCT00690898 · Registry updated: 2022-10-14

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Belgium · Czechia · Finland · France · Germany · Italy · Netherlands · Turkey (Türkiye) · United Kingdom
Registry dates and results: Start: 2008-05. Completion: 2012-02 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel 120 mg (drug)

Where the study takes place — 27 listed sites

University Hospital Antwerpen
Edegem, Belgium
Site recruitment: Not reported
Všeobecná fakultní nemocnice, Karlova Univerzita
Prague, Czechia
Site recruitment: Not reported
Helsinki University Center Hospital
Helsinki, Finland
Site recruitment: Not reported
The Turku University Central Hospital
Turku, Finland
Site recruitment: Not reported
Hopital De Bois Guillaume
Bois-Guillaume, France
Site recruitment: Not reported
CHU Henri Mondor
Créteil, France
Site recruitment: Not reported
CHU Grenoble Albert Michallon
Grenoble, France
Site recruitment: Not reported
CHRU Lille Hopital Claude Huriez
Lille, France
Site recruitment: Not reported
Groupement Hospitalier Est
Lyon, France
Site recruitment: Not reported
Hôpital de la Timone
Marseille, France
Site recruitment: Not reported
Hôpital Bicêtre
Paris, France
Site recruitment: Not reported
Hopital Haut Leveque
Pessac, France
Site recruitment: Not reported
CHU de Reims, Hopital Robert Debré
Reims, France
Site recruitment: Not reported
Friedrich-Alexander University
Erlangen, Germany
Site recruitment: Not reported
Universitatsklinikum Essen
Essen, Germany
Site recruitment: Not reported
Klinikum der Johann Wolfgang Goethe-Universität
Frankfurt, Germany
Site recruitment: Not reported
ENDOC Zentrum für Endokrine Tumoren und Praxis für Endokrinologie, Andrologie und medikamentöse Tumortherapie
Hamburg, Germany
Site recruitment: Not reported
Medizinische Klinik Innenstadt
München, Germany
Site recruitment: Not reported
AOU Policlinico "G. Martino" Messina
Messina, Italy
Site recruitment: Not reported
Università Federico II di Napoli, Dipartimento di Endocrinologia Molecolare e Clinicae Oncologia
Naples, Italy
Site recruitment: Not reported
Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, U.O.C. di Endocrinologia
Roma, Italy
Site recruitment: Not reported
ERASMUS MC Rotterdam
Rotterdam, Netherlands
Site recruitment: Not reported
UMC Utrecht
Utrecht, Netherlands
Site recruitment: Not reported
Cerrahpasa Medical Facility
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
27/28 Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Site recruitment: Not reported
Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported
Derriford Hospital
Plymouth, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

ClinicalTrials.gov · NCT00842348 · Registry updated: 2022-10-12

Condition / research focus: Non Functioning Entero-pancreatic Endocrine Tumour
Sponsor: Ipsen
Countries with listed sites: Belgium · Czechia · France · Italy · Poland · Slovakia · Spain · United Kingdom · United States
Registry dates and results: Start: 2009-02. Completion: 2015-12 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug) — also listed as: Lanreotide, Lanreotide Autogel, Somatuline, Somatuline Autogel, Somatuline Depot

Where the study takes place — 25 listed sites

Cedars-Sinai Outpatient Cancer Center
Los Angeles, California, United States
Site recruitment: Not reported
The Johns Hopkins Hospital
Baltimore, Maryland, United States
Site recruitment: Not reported
UZ Antwerpen
Antwerp, Belgium
Site recruitment: Not reported
UCL Saint Luc
Brussels, Belgium
Site recruitment: Not reported
Fakultni nemocnice Na Bulovce
Prague, Czechia
Site recruitment: Not reported
General faculty
Prague, Czechia
Site recruitment: Not reported
Hôpital Beaujon
Clichy, France
Site recruitment: Not reported
CAC Oscar Lambret
Lille, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
Hôpital R. Debré
Reims, France
Site recruitment: Not reported
Centro di Refierimiento Oncologica
Aviano, Italy
Site recruitment: Not reported
INSCT
Milan, Italy
Site recruitment: Not reported
University of Naples
Naples, Italy
Site recruitment: Not reported
Azienda San Giovanni Battista
Torino, Italy
Site recruitment: Not reported
Centrum Diagnostyczno-Lecznicze "Gammed"
Warsaw, Poland
Site recruitment: Not reported
Zaklad Diagnosttyki Radiologicznej, Centralny Szpital Klincny
Warsaw, Poland
Site recruitment: Not reported
Narodny onkologicky ustav
Bratislava, Slovakia
Site recruitment: Not reported
Hospital Vall d'Hebron
Barcelona, Spain
Site recruitment: Not reported
Institut Catala Oncologia
Barcelona, Spain
Site recruitment: Not reported
University Hospital Wales
Cardiff, United Kingdom
Site recruitment: Not reported
Western General Hospital
Edinburgh, United Kingdom
Site recruitment: Not reported
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Site recruitment: Not reported
St James Hospital
Leeds, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
QMC
Nottingham, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

ClinicalTrials.gov · NCT02651987 · Registry updated: 2022-10-03

Condition / research focus: Pancreatic Tumours; Midgut Neuroendocrine Tumours
Sponsor: Ipsen
Countries with listed sites: Belgium · Denmark · France · Germany · Ireland · Italy · Netherlands · Poland · Spain · United Kingdom
Registry dates and results: Start: 2015-12-15. Completion: 2019-10-24 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel 120 mg (drug)

Where the study takes place — 32 listed sites

Erasme Hospital
Brussels, Belgium
Site recruitment: Not reported
Cliniques Unversitaires Saint Luc
Brussels, Belgium
Site recruitment: Not reported
Antwerp University Hospital
Edegem, Belgium
Site recruitment: Not reported
UZ Leuven
Leuven, Belgium
Site recruitment: Not reported
Aarhus University Hospital
Aarhus, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Hôpital Beaujon
Clichy, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
Institut Paoli Calmette
Marseille, France
Site recruitment: Not reported
Institut Gustave Roussy
Villejuif, France
Site recruitment: Not reported
Charité - CVK
Berlin, Germany
Site recruitment: Not reported
Universitätsklinikum Erlangen
Erlangen, Germany
Site recruitment: Not reported
Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, Germany
Site recruitment: Not reported
St Vincent's University Hospital
Dublin, Ireland
Site recruitment: Not reported
IRCCS Azienda Ospedaliera Universitaria
San Martino, Genova, Italy
Site recruitment: Not reported
Azienda Ospedaliera - Universitaria Careggi
Florence, Italy
Site recruitment: Not reported
Fondacione IRCCS Istituto Nazionale Dei Tumori
Milan, Italy
Site recruitment: Not reported
Università degli Studi "Federico II" di Napoli
Naples, Italy
Site recruitment: Not reported
Azienda Ospedaliera sant'Andrea
Roma, Italy
Site recruitment: Not reported
AVL/NKI Medisch Oncologie
Amsterdam, Netherlands
Site recruitment: Not reported
Academic Medical Center
Amsterdam, Netherlands
Site recruitment: Not reported
Erasmus MC
Rotterdam, Netherlands
Site recruitment: Not reported
Samodzielny Publiczny Szpital Kliniczny nr 5
Katowice, Poland
Site recruitment: Not reported
Katedra i Klinika Endokrynologii
Poznan, Poland
Site recruitment: Not reported
Centrum Diagnostyczno-Lecznicze "GAMMED"
Warsaw, Poland
Site recruitment: Not reported
Hospital Universitario Vall D'hebron
Barcelona, Spain
Site recruitment: Not reported
Hospital Universitario Ramón Y Cajal
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario 12 De Octubre
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario Central de Asturias
Oviedo, Spain
Site recruitment: Not reported
Queen Elizabeth Medical Center
Birmingham, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
The Christie Hospital NHS Foundation Trust
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

ClinicalTrials.gov · NCT00383708 · Registry updated: 2022-09-27

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Czechia · Denmark · France · Germany · Greece · Italy · Netherlands · Spain · Sweden · United Kingdom
Registry dates and results: Start: 2006-10. Completion: 2008-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug)
Pegvisomant (drug)

Where the study takes place — 24 listed sites

University Hospital, Charles University
Hradec Králové, Czechia
Site recruitment: Not reported
Charles University
Prague, Czechia
Site recruitment: Not reported
Aarhus Kommunehospital
Aarhus, Denmark
Site recruitment: Not reported
Groupe Hospitalier Henri Mondor- Albert Chenevier
Créteil, France
Site recruitment: Not reported
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
Clinique Marc Linquette
Lille, France
Site recruitment: Not reported
Hôpital de la Timone
Marseille, France
Site recruitment: Not reported
CHU de Rangueil
Toulouse, France
Site recruitment: Not reported
Charite Campus Mitte
Berlin, Germany
Site recruitment: Not reported
Klinikum Johann Wolfgang Goethe-Universität
Frankfurt, Germany
Site recruitment: Not reported
Medizinische Klinik Innenstadt
München, Germany
Site recruitment: Not reported
Anticancer Hospital Metaxa Piraeus
Piraeus, Greece
Site recruitment: Not reported
Universitá degli Studi di Milano
Milan, Italy
Site recruitment: Not reported
University Federico II
Naples, Italy
Site recruitment: Not reported
Universitá di Torino
Torino, Italy
Site recruitment: Not reported
Leiden University Medical Center
Leiden, Netherlands
Site recruitment: Not reported
Dept. of Internal Medicine Erasmus MC
Rotterdam, Netherlands
Site recruitment: Not reported
Hospital General de Alicante
Alicante, Spain
Site recruitment: Not reported
Clínica Puerta de Hierro
Madrid, Spain
Site recruitment: Not reported
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, Spain
Site recruitment: Not reported
Sahlgrenska University Hospital
Gothenburg, Sweden
Site recruitment: Not reported
Uppsala University Hospital
Uppsala, Sweden
Site recruitment: Not reported
Christie Hospital and Holt Radium Institute
Manchester, United Kingdom
Site recruitment: Not reported
Royal Hallamshire Hospital
Sheffield, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

ClinicalTrials.gov · NCT02683941 · Registry updated: 2022-07-06

Condition / research focus: Neuroendocrine Tumors in Lung
Sponsor: Ipsen
Countries with listed sites: Austria · Canada · Denmark · France · Germany · Italy · Netherlands · Poland · Spain · United Kingdom · United States
Registry dates and results: Start: 2017-03-06. Completion: 2020-02-28 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug) — also listed as: Lanreotide Depot (US)
Placebo (drug)
Best Supportive Care (drug) — also listed as: BSC

Where the study takes place — 57 listed sites

Arizona Oncology Associates
Tucson, Arizona, United States
Site recruitment: Not reported
VA Greater Los Angeles
Los Angeles, California, United States
Site recruitment: Not reported
Rocky Mountain Cancer Center
Denver, Colorado, United States
Site recruitment: Not reported
Ochsner Medical Center
New Orleans, Louisiana, United States
Site recruitment: Not reported
Dana-Farber Institute
Boston, Massachusetts, United States
Site recruitment: Not reported
Karmanos Cancer Center
Detroit, Michigan, United States
Site recruitment: Not reported
Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported
Roswell Park Cancer Center
Buffalo, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
University of Cincinnati
Cincinnati, Ohio, United States
Site recruitment: Not reported
Oregon Health and Science Center
Portland, Oregon, United States
Site recruitment: Not reported
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Texas Oncology
Dallas, Texas, United States
Site recruitment: Not reported
Texas Oncology-Forth Worth
Fort Worth, Texas, United States
Site recruitment: Not reported
AKH und Med. University Vienna Allg Krankenhaus Wien
Vienna, Austria
Site recruitment: Not reported
Klinikum Wels-Grieskirchen GmbH
Wels, Austria
Site recruitment: Not reported
Tom Baker Cancer Center
Calgary, Alberta, Canada
Site recruitment: Not reported
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Site recruitment: Not reported
McGill University Health Center
Montreal, Quebec, Canada
Site recruitment: Not reported
Saskatoon Cancer Centre
Saskatoon, Canada
Site recruitment: Not reported
Cancer Care of Manitoba
Winnipeg, Canada
Site recruitment: Not reported
Aarhus University Hospital
Aarhus, Denmark
Site recruitment: Not reported
NET-Centre, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Centre Oscar Lambret
Lille, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
CLLC, Institut Paoli Calmettes
Marseille, France
Site recruitment: Not reported
Institut du Cancer de Montpellier (ICM) Val d'Aurelle
Montpellier, France
Site recruitment: Not reported
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
Site recruitment: Not reported
Centre René Gauducheau ICO institut de Cancerologie de l'Ouest
Saint-Herblain, France
Site recruitment: Not reported
Institut Gustave Roussy
Villejuif, France
Site recruitment: Not reported
Zentralklinik Bad Berka GmbH
Bad Berka, Germany
Site recruitment: Not reported
Evangelische Lungenklinik Berlin
Berlin, Germany
Site recruitment: Not reported
Universitätsklinikum Essen (AöR)
Essen, Germany
Site recruitment: Not reported
Johann Wolfgang Goethe-Universitätsklinikum Frankfurt
Frankfurt, Germany
Site recruitment: Not reported
Universita di Genova
Genova, Italy
Site recruitment: Not reported
Insituti Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST)
Meldola, Italy
Site recruitment: Not reported
Azienda Ospedaliera Antonio Cardarelli
Naples, Italy
Site recruitment: Not reported
Azienda Ospedaliera Universitaria di Perugia Santa Maria della Misericordia
Perugia, Italy
Site recruitment: Not reported
Insittuto Clinico Humanitas
Rozzano, Italy
Site recruitment: Not reported
Antoni van Leeuwenhoek
Amsterdam, Netherlands
Site recruitment: Not reported
Maastricht University Medical Center
Maastricht, Netherlands
Site recruitment: Not reported
Zakladu Medycyny Nuklearne i Endokrynologii Onkologicznej
Gliwice, Poland
Site recruitment: Not reported
University Center of Ophtalmology & Oncology
Katowice, Poland
Site recruitment: Not reported
Szpital Uniwersytecki W
Krakow, Poland
Site recruitment: Not reported
Szpital Kliniczny im. H. Święcickiego U.M.
Poznan, Poland
Site recruitment: Not reported
GAMMED
Warsaw, Poland
Site recruitment: Not reported
Hospital Universitari, Vall d'Hebron
Barcelona, Spain
Site recruitment: Not reported
University Hospital Ramón y Cajal
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Site recruitment: Not reported
Hospital Universitario Miguel Servet
Zaragoza, Spain
Site recruitment: Not reported
Cancer Center, Beatson Oncology
Glasgow, United Kingdom
Site recruitment: Not reported
Royal Surrey County Hospital
Guildford, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
King's College Hospital
London, United Kingdom
Site recruitment: Not reported
Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported
Churchill Hospital
Oxford, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

ClinicalTrials.gov · NCT03174353 · Registry updated: 2022-06-16

Condition / research focus: Pancreatic Leak; Pancreatic Fistula; Pancreaticoduodenal; Fistula; Pancreatectomy; Hyperglycemia
Sponsor: University of Washington
Countries with listed sites: United States
Registry dates and results: Start: 2018-02-20. Completion: 2021-04-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Prefilled Syringe (drug) — also listed as: Somatuline Depot 120 Mg/0.5Ml Solution for Injection

Where the study takes place — 1 listed sites

University of Washington Medical Center
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

ClinicalTrials.gov · NCT02685709 · Registry updated: 2022-04-22

Condition / research focus: Acromegaly
Sponsor: Chiasma, Inc.
Countries with listed sites: Austria · France · Germany · Hungary · Italy · Lithuania · Poland · Romania · Russia · Serbia · Spain · United Kingdom · United States
Registry dates and results: Start: 2016-02. Completion: 2021-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide capsules (drug) — also listed as: Injection SRLs

Where the study takes place — 53 listed sites

University of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
Keck Medical Center of University of Southern California
Los Angeles, California, United States
Site recruitment: Not reported
Cedars-Sinai Medical Center
Los Angeles, California, United States
Site recruitment: Not reported
Stanford University School of Medicine
Stanford, California, United States
Site recruitment: Not reported
University of Colorado Denver
Aurora, Colorado, United States
Site recruitment: Not reported
Emory University
Atlanta, Georgia, United States
Site recruitment: Not reported
Northwestern University
Chicago, Illinois, United States
Site recruitment: Not reported
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois, United States
Site recruitment: Not reported
Johns Hopkins University
Baltimore, Maryland, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
Washington University School of Medicine
St Louis, Missouri, United States
Site recruitment: Not reported
Rutgers - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Site recruitment: Not reported
Columbia University Medical Center
New York, New York, United States
Site recruitment: Not reported
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Site recruitment: Not reported
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Allegheny Endocrinology Associates
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported
Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported
Houston Methodist Research Institute
Houston, Texas, United States
Site recruitment: Not reported
Universitätsklinik für Innere Medizin Klinische Abteilung für Endokrinologie und Diabetologie
Graz, Austria
Site recruitment: Not reported
Medizinische Universität Wien
Vienna, Austria
Site recruitment: Not reported
Hospices Civils de Lyon
Bron, France
Site recruitment: Not reported
Hôpital Bicêtre APHP
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
Praxis für Endokrinologie und Diabetologie Dr M Droste
Oldenburg, Germany
Site recruitment: Not reported
Magyar Honvedseg Egeszsegugyi Kozpont
Budapest, Hungary
Site recruitment: Not reported
University of Pecs
Pécs, Hungary
Site recruitment: Not reported
Szegedi Tudományegyetem, I. Belgyógyászati Klinika
Szeged, Hungary
Site recruitment: Not reported
Policlinico di Monserrato U.O.C. Endocrinologia e Diabetologia
Monserrato, Italy
Site recruitment: Not reported
Università di Pisa Dipartimento di Medicina Clinica e Sperimentale
Pisa, Italy
Site recruitment: Not reported
Fondazione Policlinico Universitario A. Gemelli Università Cattolica del S.Cuore S.C. Endocrinologia e Malattie del Metabolismo
Rome, Italy
Site recruitment: Not reported
Hospital of LUHS Kauno Klinikos
Kaunas, Lithuania
Site recruitment: Not reported
Vaidotas Urbanavicius Individuali Imonė
Vilnius, Lithuania
Site recruitment: Not reported
Katedra i Klinika Endokrynologii i Chorob Wewnetrznych Gdanski Uniwersytet Medyczny
Gdansk, Poland
Site recruitment: Not reported
Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Klinika Endokrynologii, Diabetologii i Leczenia Izotopami
Wroclaw, Poland
Site recruitment: Not reported
"C.I. Parhon" National Institute of Endocrinology I Clinical Endocrinology Department - Endemic goitier and its complications
Bucharest, Romania
Site recruitment: Not reported
Antrium Multidisciplinary Medical Clinic
Barnaul, Russia
Site recruitment: Not reported
Interregional Clinical Diagnostic Center
Kazan', Russia
Site recruitment: Not reported
Regional State Budgetary Healthcare Institution Regional State Hospital
Krasnoyarsk, Russia
Site recruitment: Not reported
Sechenov Moscow First State Medical University
Moscow, Russia
Site recruitment: Not reported
"Atlas" Medical Center
Moscow, Russia
Site recruitment: Not reported
Vladimirsky Moscow Regional Research Clinical Institute
Moscow, Russia
Site recruitment: Not reported
Novosibirsk State Regional Clinical Hospital
Novosibirsk, Russia
Site recruitment: Not reported
Federal State Budgetary Institution "V. A. Almazov Federal North-West Medical Research Centre" of the Ministry of Health of the Russian Federation
Saint Petersburg, Russia
Site recruitment: Not reported
"Centre Diabetes" LLC
Samara, Russia
Site recruitment: Not reported
Clinical Centre of Serbia, Clinic for Endocrinology Diabetes and Metabolic Diseases
Belgrade, Serbia
Site recruitment: Not reported
Hospital Universitario de la Ribera
Alzira, Spain
Site recruitment: Not reported
Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
Site recruitment: Not reported
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Site recruitment: Not reported
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, Spain
Site recruitment: Not reported
Campus Del Hospital Universitario Virgen del Rocio
Seville, Spain
Site recruitment: Not reported
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital
Birmingham, United Kingdom
Site recruitment: Not reported
Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary
Manchester, United Kingdom
Site recruitment: Not reported
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
Site recruitment: Not reported
Royal Hallamshire Hospital
Sheffield, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:56 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

ClinicalTrials.gov · NCT04649580 · Registry updated: 2024-12-17

Condition / research focus: Neuroendocrine Tumours (NET)
Sponsor: Ipsen
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2021-04-27. Completion: 2022-06-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 5 listed sites

University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Site recruitment: Not reported
Cardiff and Vale University LHB
Cardiff, United Kingdom
Site recruitment: Not reported
University Hospitals Coventry and Warwickshire NHS Trust
Coventry, United Kingdom
Site recruitment: Not reported
Liverpool University Hospitals NHS Foundation Trust
Liverpool, United Kingdom
Site recruitment: Not reported
Royal Free London NHS Foundation Trust
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

ClinicalTrials.gov · NCT04852679 · Registry updated: 2024-10-01

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumor
Sponsor: Ipsen
Countries with listed sites: China
Registry dates and results: Start: 2021-05-24. Completion: 2023-01-13 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel (drug)

Where the study takes place — 14 listed sites

Cancer Hospital Chinese Academy of Sciences
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University Third Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Site recruitment: Not reported
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Qilu Hospital Of Shandong University
Jinan, Shandong, China
Site recruitment: Not reported
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Fudan University Shanghai Cancer Centre
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital Of Xi'an Jiaotong University
Xi’an, Shanxi, China
Site recruitment: Not reported
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
The second affiliated hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site recruitment: Not reported
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

ClinicalTrials.gov · NCT06607666 · Registry updated: 2024-09-23

Condition / research focus: Acromegaly
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Countries with listed sites: Italy
Registry dates and results: Start: 2023-01-26. Completion: 2024-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel (drug) — also listed as: Somatostatin Receptor ligand

Where the study takes place — 1 listed sites

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC ENDOCRINOLOGIA
Roma, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

ClinicalTrials.gov · NCT05701241 · Registry updated: 2024-06-14

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumor
Sponsor: University Hospital, Antwerp
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2023-06-28. Completion: 2034-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Somatostatin analog (drug) — also listed as: lanreotide, octreotide, sandostatin, somatuline

Where the study takes place — 19 listed sites

AZ Klina
Brasschaat, Antwerp, Belgium
Site recruitment: Recruiting
AZ Rivierenland
Rumst, Antwerp, Belgium
Site recruitment: Active, not recruiting
Ghent University Hospital
Ghent, East Flanders, Belgium
Site recruitment: Active, not recruiting
VITAZ
Sint-Niklaas, East-Flanders, Belgium
Site recruitment: Recruiting
University Hospital Leuven
Leuven, Flemish Brabant, Belgium
Site recruitment: Recruiting
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium
Site recruitment: Active, not recruiting
AZ Monica
Antwerp, Belgium
Site recruitment: Not yet recruiting
GZA
Antwerp, Belgium
Site recruitment: Active, not recruiting
Ziekenhuis Netwerk Antwerpen
Antwerp, Belgium
Site recruitment: Withdrawn
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Site recruitment: Recruiting
H.U.B.
Brussels, Belgium
Site recruitment: Active, not recruiting
Antwerp University Hospital
Edegem, Belgium
Site recruitment: Recruiting
Centre Hospitalier Universitaire Sart Tilman
Liège, Belgium
Site recruitment: Active, not recruiting
Rijnstate
Arnhem, Gelderland, Netherlands
Site recruitment: Recruiting
Maastricht UMC+
Maastricht, Limburg, Netherlands
Site recruitment: Recruiting
Maxima Medisch Centrum
Eindhoven, North Brabant, Netherlands
Site recruitment: Active, not recruiting
Amsterdam UMC
Amsterdam, North Holland, Netherlands
Site recruitment: Active, not recruiting
UMC Groningen
Groningen, Netherlands
Site recruitment: Recruiting
Erasmus MC
Rotterdam, Netherlands
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

ClinicalTrials.gov · NCT01070758 · Registry updated: 2024-04-18

Condition / research focus: Congenital Hyperinsulinism
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2010-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel (drug) — also listed as: Somatuline autogel

Where the study takes place — 1 listed sites

Pediatric Endocrinology Unit, Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET

ClinicalTrials.gov · NCT05922579 · Registry updated: 2024-02-29

Condition / research focus: Neuroendocrine Tumors
Sponsor: Ipsen
Countries with listed sites: Australia
Registry dates and results: Start: 2023-06-15. Completion: 2023-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

CAPPRE
Sydney, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

ClinicalTrials.gov · NCT02859064 · Registry updated: 2023-12-05

Condition / research focus: Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors
Sponsor: SCRI Development Innovations, LLC
Countries with listed sites: United States
Registry dates and results: Start: 2017-07-28. Completion: 2022-06-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline® Depot Injection
Y-90 microspheres (device) — also listed as: SIR-Spheres

Where the study takes place — 3 listed sites

Rocky Mountain Cancer Center
Denver, Colorado, United States
Site recruitment: Not reported
Research Medical Center/HCA Midwest
Kansas City, Missouri, United States
Site recruitment: Not reported
Tennessee Oncology PLLC
Nashville, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

ClinicalTrials.gov · NCT03043664 · Registry updated: 2023-06-29

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumors
Sponsor: Duke University
Countries with listed sites: United States
Registry dates and results: Start: 2017-07-01. Completion: 2022-06-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline Depot
Pembrolizumab (drug) — also listed as: Keytruda

Where the study takes place — 2 listed sites

Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Lexington Medical Center
Columbia, South Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

ClinicalTrials.gov · NCT03967249 · Registry updated: 2023-03-22

Condition / research focus: Acromegaly
Sponsor: Ionis Pharmaceuticals, Inc.
Countries with listed sites: Hungary · Lithuania · Poland · Russia · Serbia · United States
Registry dates and results: Start: 2019-07-25. Completion: 2022-07-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IONIS GHR-LRx (drug)
Somatostatin Receptor Ligand (SRL) (drug) — also listed as: lanreotide, octreotide

Where the study takes place — 22 listed sites

University of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
Northwestern University
Evanston, Illinois, United States
Site recruitment: Not reported
Palm Research Center, Inc.
Las Vegas, Nevada, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Not reported
Oregon Health & Science University
Portland, Oregon, United States
Site recruitment: Not reported
Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly
Budapest, Hungary
Site recruitment: Not reported
Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos - Endocrinology clinic
Kaunas, Lithuania
Site recruitment: Not reported
Vaidoto Urbanaviciaus Individuali imone - Endokrinologijos klinika
Vilnius, Lithuania
Site recruitment: Not reported
Centrum Nowoczesnych Terapii "Dobry Lekarz" Sp. z o. o.
Krakow, Poland
Site recruitment: Not reported
Twoja Przychodnia - Centrum Medyczne Nowa Sol
Nowa Sól, Poland
Site recruitment: Not reported
Mazowiecki Szpital Brodnowski
Warsaw, Poland
Site recruitment: Not reported
Multi-field Medical Clinic Anturium LLC
Barnaul, Russia
Site recruitment: Not reported
Interregional Clinical Diagnostic Center
Kazan', Russia
Site recruitment: Not reported
Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev
Kemerovo, Russia
Site recruitment: Not reported
Federal State Budget Institution "National Medical Research Center of Endocrinology" of the Ministry of Healthcare of the Russian Federation
Moscow, Russia
Site recruitment: Not reported
I.M. Sechenov Moscow First State Medical University
Moscow, Russia
Site recruitment: Not reported
Novosibirsk State Regional Clinical Hospital
Novosibirsk, Russia
Site recruitment: Not reported
Orenburg Regional Clinical Hospital
Orenburg, Russia
Site recruitment: Not reported
Almazov National Medical Research Centre
Saint Petersburg, Russia
Site recruitment: Not reported
State Budget Healthcare Institution of the Tver Region (Regional Clinical Hospital)
Tver', Russia
Site recruitment: Not reported
Clinical Center of Serbia
Belgrade, Serbia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

ClinicalTrials.gov · NCT01923649 · Registry updated: 2023-01-27

Condition / research focus: Dumping Syndrome
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium
Registry dates and results: Start: 2008-04. Completion: 2013-12-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide 90 mg slow release formulation (drug) — also listed as: Somatulin autogel
Placebo (drug)

Where the study takes place — 3 listed sites

AZ St. Lucas
Brugges, Belgium
Site recruitment: Not reported
ZOL Genk
Genk, Belgium
Site recruitment: Not reported
University Hospitals Leuven
Leuven, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3TerminatedINTERVENTIONAL

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

ClinicalTrials.gov · NCT02288377 · Registry updated: 2023-01-18

Condition / research focus: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Sponsor: Federation Francophone de Cancerologie Digestive
Countries with listed sites: Belgium · France · Germany · United Kingdom
Registry dates and results: Start: 2015-01. Completion: 2020-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (drug)
Placebo (drug)

Where the study takes place — 24 listed sites

Clinique Universitaire saint-Luc
Brussels, Belgium
Site recruitment: Not reported
CHU d'Angers - Hôtel Dieu
Angers, France
Site recruitment: Not reported
CHU - Hôpital Avicenne
Bobigny, France
Site recruitment: Not reported
CHU Côte de Nacre
Caen, France
Site recruitment: Not reported
CHU Estaing
Clermont-Ferrand, France
Site recruitment: Not reported
Hôpital Beaujon
Clichy, France
Site recruitment: Not reported
CHU Le Bocage Service d'HGE
Dijon, France
Site recruitment: Not reported
CH Les Oudairies
La Roche-sur-Yon, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
CHU La Timone
Marseille, France
Site recruitment: Not reported
Hôpital de la Source
Orléans, France
Site recruitment: Not reported
CHU Cochin
Paris, France
Site recruitment: Not reported
Hôpital Haut Lévêque Bat Magellan, Service d'hépato-gastroentérologie
Pessac, France
Site recruitment: Not reported
Hôpital de la Milétrie
Poitiers, France
Site recruitment: Not reported
Hôpital Robert Debré
Reims, France
Site recruitment: Not reported
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
Site recruitment: Not reported
CHU Charles Nicolle
Rouen, France
Site recruitment: Not reported
CHU de Saint Etienne
Saint-Priest-en-Jarez, France
Site recruitment: Not reported
Hôpital Rangueil
Toulouse, France
Site recruitment: Not reported
Institut Gustave Roussy
Villejuif, France
Site recruitment: Not reported
Charite Campus Virchow Kilikum
Berlin, Germany
Site recruitment: Not reported
University Hospital Marburg
Marburg, Germany
Site recruitment: Not reported
Royal Free Hospital Neuroendocrine Tumour Unit
London, United Kingdom
Site recruitment: Not reported
Manchester Academic Health Sciences Centre (MAHSC)
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Acromegaly Combination Treatment Study

ClinicalTrials.gov · NCT01538966 · Registry updated: 2023-01-04

Condition / research focus: Acromegaly
Sponsor: Cedars-Sinai Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2012-03-29. Completion: 2022-05-20 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pegvisomant (drug) — also listed as: Somavert
Octreotide LAR (drug) — also listed as: Sandostatin
Lanreotide (drug) — also listed as: Somatuline

Where the study takes place — 1 listed sites

Cedars-Sinai Medical Center
Los Angeles, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

ClinicalTrials.gov · NCT00774930 · Registry updated: 2022-10-14

Condition / research focus: Carcinoid Syndrome
Sponsor: Ipsen
Countries with listed sites: Brazil · Czechia · India · Latvia · Poland · Russia · Serbia · South Africa · Turkey (Türkiye) · Ukraine · United States
Registry dates and results: Start: 2009-05. Completion: 2015-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline, Somatuline Depot, Somatuline Autogel, Lanreotide Autogel
Placebo (drug)

Where the study takes place — 54 listed sites

VA Greater Los Angeles Health Care System
Los Angeles, California, United States
Site recruitment: Not reported
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
Site recruitment: Not reported
Stanford Cancer Center
Stanford, California, United States
Site recruitment: Not reported
Cedars Sinai Outpatient Cancer Center
West Hollywood, California, United States
Site recruitment: Not reported
Kentuckiana Cancer Institute
Louisville, Kentucky, United States
Site recruitment: Not reported
Louisiana State University Health Science Center
Kenner, Louisiana, United States
Site recruitment: Not reported
University of Michigan
Ann Arbor, Michigan, United States
Site recruitment: Not reported
University of Mississippi Medical Center
Jackson, Mississippi, United States
Site recruitment: Not reported
University of New Mexico Cancer Care Center
Albuquerque, New Mexico, United States
Site recruitment: Not reported
Providence Portland Medical Center
Portland, Oregon, United States
Site recruitment: Not reported
Oregon Health Science University
Portland, Oregon, United States
Site recruitment: Not reported
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Site recruitment: Not reported
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
UPMC Liver Cancer Center
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported
Eastern Virginia Medical School
Norfolk, Virginia, United States
Site recruitment: Not reported
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
Biocancer - Centro de Pesquisa e Tratamento do Câncer
Belo Horizonte, Brazil
Site recruitment: Not reported
Hospital LifeCenter
Belo Horizonte, Brazil
Site recruitment: Not reported
Oxion Medicina Oncológica
Belo Horizonte, Brazil
Site recruitment: Not reported
Hospital Universitário de Brasilia
Brasília, Brazil
Site recruitment: Not reported
Hospital Erasto Gaertner
Curitiba, Brazil
Site recruitment: Not reported
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Brazil
Site recruitment: Not reported
Hospital de Base de São José do Rio Preto
São José do Rio Preto, Brazil
Site recruitment: Not reported
VFN Onkologicka klinika
Prague, Czechia
Site recruitment: Not reported
Sir Gangaram Hospital
Delhi, India
Site recruitment: Not reported
Indo-American Cancer Institute & Research Centre
Hyderabad, India
Site recruitment: Not reported
Omega Hospitals
Hyderabad, India
Site recruitment: Not reported
Santokaba Durlabhji Memorial Hospital and Research Institute
Jaipur, India
Site recruitment: Not reported
Bhagwan Mahaveer cancer hospital and research centre
Jaipur, India
Site recruitment: Not reported
Shatabdi Super Speciality hospital
Mumbai, India
Site recruitment: Not reported
Tata Memorial Hospital
Mumbai, India
Site recruitment: Not reported
Paul Stradins Clinical University Hospital
Riga, Latvia
Site recruitment: Not reported
Klinika Endokrynologii, Diabetologii i Leczenia Izotopami
Wroclaw, Poland
Site recruitment: Not reported
Non-Federal Institution of Healthcare "Central Clinical Hospital # 1 of the LLC "Russian Railways (RZD)"
Moscow, Russia
Site recruitment: Not reported
Russian Academy of Medical Sciences "Russian Oncological Research Centre named after N.N. Blokhin RAMS"
Moscow, Russia
Site recruitment: Not reported
Federal Institution of Healthcare "Leningradsky Regional Oncological Dispensary"
Saint Petersburg, Russia
Site recruitment: Not reported
Clinic of Endocrinology, diabetes and metabolic diseases, Clinical Center of Serbia
Belgrade, Serbia
Site recruitment: Not reported
Oncology Institute of Vojvodina, Sremska Kamenica
Kamenitz, Serbia
Site recruitment: Not reported
Rondebosch Oncology Unit
Cape Town, South Africa
Site recruitment: Not reported
Groote Schuur Hospital
Cape Town, South Africa
Site recruitment: Not reported
Westridge Medical Centre
Durban, South Africa
Site recruitment: Not reported
GVI Oncology Clinical Trial Unit
Port Elizabeth, South Africa
Site recruitment: Not reported
Erciyes University Medical Faculty
Kayseri, Turkey (Türkiye)
Site recruitment: Not reported
Cherkassy Regional Oncology Dispensary
Cherkassy, Ukraine
Site recruitment: Not reported
Chernivtsi Regional Oncology Center
Chernivtsi, Ukraine
Site recruitment: Not reported
Oncology and Medical Radiology Chair of Dnepropetrovsk State Medical Academy
Dnipro, Ukraine
Site recruitment: Not reported
Regional Anticancer Center, Department of oncoproctology
Donetsk, Ukraine
Site recruitment: Not reported
Municipal Clinical Hospital #2, Proctology department
Kharkiv, Ukraine
Site recruitment: Not reported
Kyiv City Oncological Hospital, Thoracic department
Kyiv, Ukraine
Site recruitment: Not reported
Medical Centre "Mriya"
Kyiv, Ukraine
Site recruitment: Not reported
National Cancer Institute
Kyiv, Ukraine
Site recruitment: Not reported
Odessa Regional Clinical Hospital
Odesa, Ukraine
Site recruitment: Not reported
Uzhgorods'ka Tsentral'na Mis'ka Klinichna Likarnya, Mis'kyy Onkologichnyy Tsentr
Uzhhorod, Ukraine
Site recruitment: Not reported
Vinnytsya Regional Clinical Oncological Center, Vinnytsya State Medical University
Vinnytsia, Ukraine
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

ClinicalTrials.gov · NCT00690898 · Registry updated: 2022-10-14

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Belgium · Czechia · Finland · France · Germany · Italy · Netherlands · Turkey (Türkiye) · United Kingdom
Registry dates and results: Start: 2008-05. Completion: 2012-02 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel 120 mg (drug)

Where the study takes place — 27 listed sites

University Hospital Antwerpen
Edegem, Belgium
Site recruitment: Not reported
Všeobecná fakultní nemocnice, Karlova Univerzita
Prague, Czechia
Site recruitment: Not reported
Helsinki University Center Hospital
Helsinki, Finland
Site recruitment: Not reported
The Turku University Central Hospital
Turku, Finland
Site recruitment: Not reported
Hopital De Bois Guillaume
Bois-Guillaume, France
Site recruitment: Not reported
CHU Henri Mondor
Créteil, France
Site recruitment: Not reported
CHU Grenoble Albert Michallon
Grenoble, France
Site recruitment: Not reported
CHRU Lille Hopital Claude Huriez
Lille, France
Site recruitment: Not reported
Groupement Hospitalier Est
Lyon, France
Site recruitment: Not reported
Hôpital de la Timone
Marseille, France
Site recruitment: Not reported
Hôpital Bicêtre
Paris, France
Site recruitment: Not reported
Hopital Haut Leveque
Pessac, France
Site recruitment: Not reported
CHU de Reims, Hopital Robert Debré
Reims, France
Site recruitment: Not reported
Friedrich-Alexander University
Erlangen, Germany
Site recruitment: Not reported
Universitatsklinikum Essen
Essen, Germany
Site recruitment: Not reported
Klinikum der Johann Wolfgang Goethe-Universität
Frankfurt, Germany
Site recruitment: Not reported
ENDOC Zentrum für Endokrine Tumoren und Praxis für Endokrinologie, Andrologie und medikamentöse Tumortherapie
Hamburg, Germany
Site recruitment: Not reported
Medizinische Klinik Innenstadt
München, Germany
Site recruitment: Not reported
AOU Policlinico "G. Martino" Messina
Messina, Italy
Site recruitment: Not reported
Università Federico II di Napoli, Dipartimento di Endocrinologia Molecolare e Clinicae Oncologia
Naples, Italy
Site recruitment: Not reported
Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, U.O.C. di Endocrinologia
Roma, Italy
Site recruitment: Not reported
ERASMUS MC Rotterdam
Rotterdam, Netherlands
Site recruitment: Not reported
UMC Utrecht
Utrecht, Netherlands
Site recruitment: Not reported
Cerrahpasa Medical Facility
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
27/28 Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Site recruitment: Not reported
Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported
Derriford Hospital
Plymouth, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

ClinicalTrials.gov · NCT00842348 · Registry updated: 2022-10-12

Condition / research focus: Non Functioning Entero-pancreatic Endocrine Tumour
Sponsor: Ipsen
Countries with listed sites: Belgium · Czechia · France · Italy · Poland · Slovakia · Spain · United Kingdom · United States
Registry dates and results: Start: 2009-02. Completion: 2015-12 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug) — also listed as: Lanreotide, Lanreotide Autogel, Somatuline, Somatuline Autogel, Somatuline Depot

Where the study takes place — 25 listed sites

Cedars-Sinai Outpatient Cancer Center
Los Angeles, California, United States
Site recruitment: Not reported
The Johns Hopkins Hospital
Baltimore, Maryland, United States
Site recruitment: Not reported
UZ Antwerpen
Antwerp, Belgium
Site recruitment: Not reported
UCL Saint Luc
Brussels, Belgium
Site recruitment: Not reported
Fakultni nemocnice Na Bulovce
Prague, Czechia
Site recruitment: Not reported
General faculty
Prague, Czechia
Site recruitment: Not reported
Hôpital Beaujon
Clichy, France
Site recruitment: Not reported
CAC Oscar Lambret
Lille, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
Hôpital R. Debré
Reims, France
Site recruitment: Not reported
Centro di Refierimiento Oncologica
Aviano, Italy
Site recruitment: Not reported
INSCT
Milan, Italy
Site recruitment: Not reported
University of Naples
Naples, Italy
Site recruitment: Not reported
Azienda San Giovanni Battista
Torino, Italy
Site recruitment: Not reported
Centrum Diagnostyczno-Lecznicze "Gammed"
Warsaw, Poland
Site recruitment: Not reported
Zaklad Diagnosttyki Radiologicznej, Centralny Szpital Klincny
Warsaw, Poland
Site recruitment: Not reported
Narodny onkologicky ustav
Bratislava, Slovakia
Site recruitment: Not reported
Hospital Vall d'Hebron
Barcelona, Spain
Site recruitment: Not reported
Institut Catala Oncologia
Barcelona, Spain
Site recruitment: Not reported
University Hospital Wales
Cardiff, United Kingdom
Site recruitment: Not reported
Western General Hospital
Edinburgh, United Kingdom
Site recruitment: Not reported
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Site recruitment: Not reported
St James Hospital
Leeds, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
QMC
Nottingham, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

ClinicalTrials.gov · NCT02651987 · Registry updated: 2022-10-03

Condition / research focus: Pancreatic Tumours; Midgut Neuroendocrine Tumours
Sponsor: Ipsen
Countries with listed sites: Belgium · Denmark · France · Germany · Ireland · Italy · Netherlands · Poland · Spain · United Kingdom
Registry dates and results: Start: 2015-12-15. Completion: 2019-10-24 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel 120 mg (drug)

Where the study takes place — 32 listed sites

Erasme Hospital
Brussels, Belgium
Site recruitment: Not reported
Cliniques Unversitaires Saint Luc
Brussels, Belgium
Site recruitment: Not reported
Antwerp University Hospital
Edegem, Belgium
Site recruitment: Not reported
UZ Leuven
Leuven, Belgium
Site recruitment: Not reported
Aarhus University Hospital
Aarhus, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Hôpital Beaujon
Clichy, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
Institut Paoli Calmette
Marseille, France
Site recruitment: Not reported
Institut Gustave Roussy
Villejuif, France
Site recruitment: Not reported
Charité - CVK
Berlin, Germany
Site recruitment: Not reported
Universitätsklinikum Erlangen
Erlangen, Germany
Site recruitment: Not reported
Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, Germany
Site recruitment: Not reported
St Vincent's University Hospital
Dublin, Ireland
Site recruitment: Not reported
IRCCS Azienda Ospedaliera Universitaria
San Martino, Genova, Italy
Site recruitment: Not reported
Azienda Ospedaliera - Universitaria Careggi
Florence, Italy
Site recruitment: Not reported
Fondacione IRCCS Istituto Nazionale Dei Tumori
Milan, Italy
Site recruitment: Not reported
Università degli Studi "Federico II" di Napoli
Naples, Italy
Site recruitment: Not reported
Azienda Ospedaliera sant'Andrea
Roma, Italy
Site recruitment: Not reported
AVL/NKI Medisch Oncologie
Amsterdam, Netherlands
Site recruitment: Not reported
Academic Medical Center
Amsterdam, Netherlands
Site recruitment: Not reported
Erasmus MC
Rotterdam, Netherlands
Site recruitment: Not reported
Samodzielny Publiczny Szpital Kliniczny nr 5
Katowice, Poland
Site recruitment: Not reported
Katedra i Klinika Endokrynologii
Poznan, Poland
Site recruitment: Not reported
Centrum Diagnostyczno-Lecznicze "GAMMED"
Warsaw, Poland
Site recruitment: Not reported
Hospital Universitario Vall D'hebron
Barcelona, Spain
Site recruitment: Not reported
Hospital Universitario Ramón Y Cajal
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario 12 De Octubre
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario Central de Asturias
Oviedo, Spain
Site recruitment: Not reported
Queen Elizabeth Medical Center
Birmingham, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
The Christie Hospital NHS Foundation Trust
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

ClinicalTrials.gov · NCT00383708 · Registry updated: 2022-09-27

Condition / research focus: Acromegaly
Sponsor: Ipsen
Countries with listed sites: Czechia · Denmark · France · Germany · Greece · Italy · Netherlands · Spain · Sweden · United Kingdom
Registry dates and results: Start: 2006-10. Completion: 2008-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (Autogel formulation) (drug)
Pegvisomant (drug)

Where the study takes place — 24 listed sites

University Hospital, Charles University
Hradec Králové, Czechia
Site recruitment: Not reported
Charles University
Prague, Czechia
Site recruitment: Not reported
Aarhus Kommunehospital
Aarhus, Denmark
Site recruitment: Not reported
Groupe Hospitalier Henri Mondor- Albert Chenevier
Créteil, France
Site recruitment: Not reported
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
Clinique Marc Linquette
Lille, France
Site recruitment: Not reported
Hôpital de la Timone
Marseille, France
Site recruitment: Not reported
CHU de Rangueil
Toulouse, France
Site recruitment: Not reported
Charite Campus Mitte
Berlin, Germany
Site recruitment: Not reported
Klinikum Johann Wolfgang Goethe-Universität
Frankfurt, Germany
Site recruitment: Not reported
Medizinische Klinik Innenstadt
München, Germany
Site recruitment: Not reported
Anticancer Hospital Metaxa Piraeus
Piraeus, Greece
Site recruitment: Not reported
Universitá degli Studi di Milano
Milan, Italy
Site recruitment: Not reported
University Federico II
Naples, Italy
Site recruitment: Not reported
Universitá di Torino
Torino, Italy
Site recruitment: Not reported
Leiden University Medical Center
Leiden, Netherlands
Site recruitment: Not reported
Dept. of Internal Medicine Erasmus MC
Rotterdam, Netherlands
Site recruitment: Not reported
Hospital General de Alicante
Alicante, Spain
Site recruitment: Not reported
Clínica Puerta de Hierro
Madrid, Spain
Site recruitment: Not reported
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, Spain
Site recruitment: Not reported
Sahlgrenska University Hospital
Gothenburg, Sweden
Site recruitment: Not reported
Uppsala University Hospital
Uppsala, Sweden
Site recruitment: Not reported
Christie Hospital and Holt Radium Institute
Manchester, United Kingdom
Site recruitment: Not reported
Royal Hallamshire Hospital
Sheffield, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

ClinicalTrials.gov · NCT02683941 · Registry updated: 2022-07-06

Condition / research focus: Neuroendocrine Tumors in Lung
Sponsor: Ipsen
Countries with listed sites: Austria · Canada · Denmark · France · Germany · Italy · Netherlands · Poland · Spain · United Kingdom · United States
Registry dates and results: Start: 2017-03-06. Completion: 2020-02-28 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (Autogel formulation) (drug) — also listed as: Lanreotide Depot (US)
Placebo (drug)
Best Supportive Care (drug) — also listed as: BSC

Where the study takes place — 57 listed sites

Arizona Oncology Associates
Tucson, Arizona, United States
Site recruitment: Not reported
VA Greater Los Angeles
Los Angeles, California, United States
Site recruitment: Not reported
Rocky Mountain Cancer Center
Denver, Colorado, United States
Site recruitment: Not reported
Ochsner Medical Center
New Orleans, Louisiana, United States
Site recruitment: Not reported
Dana-Farber Institute
Boston, Massachusetts, United States
Site recruitment: Not reported
Karmanos Cancer Center
Detroit, Michigan, United States
Site recruitment: Not reported
Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported
Roswell Park Cancer Center
Buffalo, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
University of Cincinnati
Cincinnati, Ohio, United States
Site recruitment: Not reported
Oregon Health and Science Center
Portland, Oregon, United States
Site recruitment: Not reported
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Texas Oncology
Dallas, Texas, United States
Site recruitment: Not reported
Texas Oncology-Forth Worth
Fort Worth, Texas, United States
Site recruitment: Not reported
AKH und Med. University Vienna Allg Krankenhaus Wien
Vienna, Austria
Site recruitment: Not reported
Klinikum Wels-Grieskirchen GmbH
Wels, Austria
Site recruitment: Not reported
Tom Baker Cancer Center
Calgary, Alberta, Canada
Site recruitment: Not reported
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Site recruitment: Not reported
McGill University Health Center
Montreal, Quebec, Canada
Site recruitment: Not reported
Saskatoon Cancer Centre
Saskatoon, Canada
Site recruitment: Not reported
Cancer Care of Manitoba
Winnipeg, Canada
Site recruitment: Not reported
Aarhus University Hospital
Aarhus, Denmark
Site recruitment: Not reported
NET-Centre, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Centre Oscar Lambret
Lille, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
CLLC, Institut Paoli Calmettes
Marseille, France
Site recruitment: Not reported
Institut du Cancer de Montpellier (ICM) Val d'Aurelle
Montpellier, France
Site recruitment: Not reported
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
Site recruitment: Not reported
Centre René Gauducheau ICO institut de Cancerologie de l'Ouest
Saint-Herblain, France
Site recruitment: Not reported
Institut Gustave Roussy
Villejuif, France
Site recruitment: Not reported
Zentralklinik Bad Berka GmbH
Bad Berka, Germany
Site recruitment: Not reported
Evangelische Lungenklinik Berlin
Berlin, Germany
Site recruitment: Not reported
Universitätsklinikum Essen (AöR)
Essen, Germany
Site recruitment: Not reported
Johann Wolfgang Goethe-Universitätsklinikum Frankfurt
Frankfurt, Germany
Site recruitment: Not reported
Universita di Genova
Genova, Italy
Site recruitment: Not reported
Insituti Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST)
Meldola, Italy
Site recruitment: Not reported
Azienda Ospedaliera Antonio Cardarelli
Naples, Italy
Site recruitment: Not reported
Azienda Ospedaliera Universitaria di Perugia Santa Maria della Misericordia
Perugia, Italy
Site recruitment: Not reported
Insittuto Clinico Humanitas
Rozzano, Italy
Site recruitment: Not reported
Antoni van Leeuwenhoek
Amsterdam, Netherlands
Site recruitment: Not reported
Maastricht University Medical Center
Maastricht, Netherlands
Site recruitment: Not reported
Zakladu Medycyny Nuklearne i Endokrynologii Onkologicznej
Gliwice, Poland
Site recruitment: Not reported
University Center of Ophtalmology & Oncology
Katowice, Poland
Site recruitment: Not reported
Szpital Uniwersytecki W
Krakow, Poland
Site recruitment: Not reported
Szpital Kliniczny im. H. Święcickiego U.M.
Poznan, Poland
Site recruitment: Not reported
GAMMED
Warsaw, Poland
Site recruitment: Not reported
Hospital Universitari, Vall d'Hebron
Barcelona, Spain
Site recruitment: Not reported
University Hospital Ramón y Cajal
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Site recruitment: Not reported
Hospital Universitario Miguel Servet
Zaragoza, Spain
Site recruitment: Not reported
Cancer Center, Beatson Oncology
Glasgow, United Kingdom
Site recruitment: Not reported
Royal Surrey County Hospital
Guildford, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
King's College Hospital
London, United Kingdom
Site recruitment: Not reported
Christie Hospital
Manchester, United Kingdom
Site recruitment: Not reported
Churchill Hospital
Oxford, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

ClinicalTrials.gov · NCT03174353 · Registry updated: 2022-06-16

Condition / research focus: Pancreatic Leak; Pancreatic Fistula; Pancreaticoduodenal; Fistula; Pancreatectomy; Hyperglycemia
Sponsor: University of Washington
Countries with listed sites: United States
Registry dates and results: Start: 2018-02-20. Completion: 2021-04-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Prefilled Syringe (drug) — also listed as: Somatuline Depot 120 Mg/0.5Ml Solution for Injection

Where the study takes place — 1 listed sites

University of Washington Medical Center
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

ClinicalTrials.gov · NCT02685709 · Registry updated: 2022-04-22

Condition / research focus: Acromegaly
Sponsor: Chiasma, Inc.
Countries with listed sites: Austria · France · Germany · Hungary · Italy · Lithuania · Poland · Romania · Russia · Serbia · Spain · United Kingdom · United States
Registry dates and results: Start: 2016-02. Completion: 2021-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide capsules (drug) — also listed as: Injection SRLs

Where the study takes place — 53 listed sites

University of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
Keck Medical Center of University of Southern California
Los Angeles, California, United States
Site recruitment: Not reported
Cedars-Sinai Medical Center
Los Angeles, California, United States
Site recruitment: Not reported
Stanford University School of Medicine
Stanford, California, United States
Site recruitment: Not reported
University of Colorado Denver
Aurora, Colorado, United States
Site recruitment: Not reported
Emory University
Atlanta, Georgia, United States
Site recruitment: Not reported
Northwestern University
Chicago, Illinois, United States
Site recruitment: Not reported
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois, United States
Site recruitment: Not reported
Johns Hopkins University
Baltimore, Maryland, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
Washington University School of Medicine
St Louis, Missouri, United States
Site recruitment: Not reported
Rutgers - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Site recruitment: Not reported
Columbia University Medical Center
New York, New York, United States
Site recruitment: Not reported
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Site recruitment: Not reported
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Allegheny Endocrinology Associates
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported
Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported
Houston Methodist Research Institute
Houston, Texas, United States
Site recruitment: Not reported
Universitätsklinik für Innere Medizin Klinische Abteilung für Endokrinologie und Diabetologie
Graz, Austria
Site recruitment: Not reported
Medizinische Universität Wien
Vienna, Austria
Site recruitment: Not reported
Hospices Civils de Lyon
Bron, France
Site recruitment: Not reported
Hôpital Bicêtre APHP
Le Kremlin-Bicêtre, France
Site recruitment: Not reported
Praxis für Endokrinologie und Diabetologie Dr M Droste
Oldenburg, Germany
Site recruitment: Not reported
Magyar Honvedseg Egeszsegugyi Kozpont
Budapest, Hungary
Site recruitment: Not reported
University of Pecs
Pécs, Hungary
Site recruitment: Not reported
Szegedi Tudományegyetem, I. Belgyógyászati Klinika
Szeged, Hungary
Site recruitment: Not reported
Policlinico di Monserrato U.O.C. Endocrinologia e Diabetologia
Monserrato, Italy
Site recruitment: Not reported
Università di Pisa Dipartimento di Medicina Clinica e Sperimentale
Pisa, Italy
Site recruitment: Not reported
Fondazione Policlinico Universitario A. Gemelli Università Cattolica del S.Cuore S.C. Endocrinologia e Malattie del Metabolismo
Rome, Italy
Site recruitment: Not reported
Hospital of LUHS Kauno Klinikos
Kaunas, Lithuania
Site recruitment: Not reported
Vaidotas Urbanavicius Individuali Imonė
Vilnius, Lithuania
Site recruitment: Not reported
Katedra i Klinika Endokrynologii i Chorob Wewnetrznych Gdanski Uniwersytet Medyczny
Gdansk, Poland
Site recruitment: Not reported
Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Klinika Endokrynologii, Diabetologii i Leczenia Izotopami
Wroclaw, Poland
Site recruitment: Not reported
"C.I. Parhon" National Institute of Endocrinology I Clinical Endocrinology Department - Endemic goitier and its complications
Bucharest, Romania
Site recruitment: Not reported
Antrium Multidisciplinary Medical Clinic
Barnaul, Russia
Site recruitment: Not reported
Interregional Clinical Diagnostic Center
Kazan', Russia
Site recruitment: Not reported
Regional State Budgetary Healthcare Institution Regional State Hospital
Krasnoyarsk, Russia
Site recruitment: Not reported
Sechenov Moscow First State Medical University
Moscow, Russia
Site recruitment: Not reported
"Atlas" Medical Center
Moscow, Russia
Site recruitment: Not reported
Vladimirsky Moscow Regional Research Clinical Institute
Moscow, Russia
Site recruitment: Not reported
Novosibirsk State Regional Clinical Hospital
Novosibirsk, Russia
Site recruitment: Not reported
Federal State Budgetary Institution "V. A. Almazov Federal North-West Medical Research Centre" of the Ministry of Health of the Russian Federation
Saint Petersburg, Russia
Site recruitment: Not reported
"Centre Diabetes" LLC
Samara, Russia
Site recruitment: Not reported
Clinical Centre of Serbia, Clinic for Endocrinology Diabetes and Metabolic Diseases
Belgrade, Serbia
Site recruitment: Not reported
Hospital Universitario de la Ribera
Alzira, Spain
Site recruitment: Not reported
Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
Site recruitment: Not reported
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Site recruitment: Not reported
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, Spain
Site recruitment: Not reported
Campus Del Hospital Universitario Virgen del Rocio
Seville, Spain
Site recruitment: Not reported
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital
Birmingham, United Kingdom
Site recruitment: Not reported
Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary
Manchester, United Kingdom
Site recruitment: Not reported
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
Site recruitment: Not reported
Royal Hallamshire Hospital
Sheffield, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →